Amgen Shares Up 8.2% on EPS Estimate Revisions and $9.87B Revenue Beat
Over the past month, Amgen shares returned 8.2% versus a 7.6% gain for the Medical - Biomedical and Genetics industry, driven by upward revisions to consensus EPS estimates (+1.8% for Q1, +2.9% for FY2026 and +4.8% for FY2027). The biotech's last quarter saw revenue of $9.87 billion (+8.6% YoY) and an EPS surprise of +11.1%, while valuation metrics remain in line with peers at a C grade.
1. Share Performance Trends
Over the past month, Amgen shares climbed 8.2% compared with a 7.6% increase for the Medical - Biomedical and Genetics industry, making it one of the top-performing names in its sector.
2. EPS Estimate Revisions
Sell-side analysts have raised the consensus EPS estimate by 1.8% for the current quarter, 2.9% for the current fiscal year and 4.8% for the next fiscal year, reflecting improved visibility into the company’s earnings trajectory.
3. Recent Quarter Results
Amgen reported revenue of $9.87 billion in its most recent quarter, up 8.6% year-over-year, and delivered EPS of $5.29, surpassing consensus estimates by 11.1% and marking its fourth straight quarter of upside surprises.
4. Valuation Profile
The company’s valuation multiples are graded C relative to peers, indicating its shares trade roughly in line with comparable biotech firms without a significant premium or discount.